Upperton Pharma Solutions is a specialist CDMO (contract development and manufacturing organisation) providing formulation and dosage form development and clinical trial manufacturing services to the biotechnology and pharmaceutical industries. We offer our clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing. We enhance the performance and delivery of our client’s products by utilising an extensive range of formulation technologies. In particular, we have world-leading expertise and know-how in pharmaceutical spray drying, with our founder having extensive expertise in this area. We have a long history of working with oral, nasal, pulmonary and parenteral dosage forms, with a new Annex 1 aligned sterile facility due to open in 2026, and an existing GMP facility with state of the art equipment. Upperton has a multinational client base, ranging from virtual and small start-up biotechs to global pharma companies. We pride ourselves on our client-focused, collaborative way of working, in addition to our flexible approach and scientific excellence.
Looking for a particular Upperton Pharma Solutions employee's phone or email?
The Upperton Pharma Solutions annual revenue was $40.8 million in 2026.
Nikki Whitfield is the CEO of Upperton Pharma Solutions.
97 people are employed at Upperton Pharma Solutions.
Upperton Pharma Solutions is based in Beeston, England.
The NAICS codes for Upperton Pharma Solutions are [32541, 32, 3254, 325].
The SIC codes for Upperton Pharma Solutions are [28, 283].